Abstract
Cryoablation is one of several therapeutic interventions that can result in thermal tissue destruction. This technique has well- documented scientific evidence supporting its efficacy as a treatment modality in the treatment of both benign and malignant diseases [1–3]. The operative mechanism produced by freezing is the extraction of heat from the targeted tissue that initiates a series of destructive events. The severity of the freezing process has long been recognized to result in a tissue response varying from inflammation to total destruction. Histologically freezing produces an area of central necrosis with a surrounding peripheral rim in which cell death is apparent [4, 5]. Successful tissue destruction resulting from cryoablation is founded on two scientific principles; first the cellular response to freezing itself and second to operative procedural factors. Freezing tissue induces cell death by setting off a cascade of events that include freeze rupture, necrosis and apoptosis. As ice forms in the targeted tissue, water is extracted from the extracellular space forming pure crystalline ice leaving behind hyperosmotic fluid in the extracellular compartment. As a consequence of this physical event, intracellular water moves to the extracellular space followed by cell shrinkage and damage to the intracellular matrix including proteins resulting from the increased salinity. In an anatomic constrained structure such as the prostate which is not totally encapsulated the expanding ice front and the spear-like ice crystals destroy both prostate cells and the capillary endothelial lining, the latter impairing the vascular tree after thawing [6]. In addition to the physical rupture of targeted tissue cells from the intracellular ice crystal formation apoptosis has been linked to thermal injury [7]. Hollister et al. have reported that after a freezing insult, prostate cancer cells die at temperatures consistent with the freeze-zone margin [8]. Induction of the apoptotic event is said to be associated with an intrinsic mitochondria induced mechanism characterized by the upregulation of cellular Bax, the pro-apoptotic protein [9]. More recently, prostate cancer cell apoptotic induction has been reported to be facilitated through an extrinsic pathway involving the interaction of tumor necrosis factor-related apoptosis-inducing ligand with its ligand in the plasma membrane [10].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Baust JG, Gage AA, Klossner D, Clark D, Miller R, Cohen J, et al. Issues critical to the successful application of cryosurgical ablation of the prostate. Technol Cancer Res Treat. 2007;6:97–109.
Gage AA, Baust JG. Cryosurgery of tumors. J Am Coll Surg. 2007;201:342–56.
Hoffmann NE, Bischof JC. The cryobiology of cryosurgical injury. Urology. 2002;60:40–9.
Gage AA, Baust J. Mechanism if tissue injury in cryosurgery. Cryobiology. 1998;37:171–86.
Larson TR, Robertson DW, Corcia A, Bostwich DG. In vivo interstitial temperature mapping of human prostate during cryosurgery with correlation to histopathologic outcomes. Urology. 2000;55(4):547–52.
Ayala AG, Ro JY, Babaian RJ, Troncoso P, Grignon D. The prostate capsule: does it exist? Its importance in staging and treatment of prostatic carcinoma. Am J Surg Pathol. 1989;13(1):21–7.
Baust JG, Gage AA, Clarke D, Baust JM, Van Buskirk R. Cryosurgery – a putative approach to molecular-based optimization. Cryobiology. 2004;48:190–204.
Hollister WR, Mathew AJ, Baust JG, Van Buskirk RG. Effects of freezing on cell viability and mechanism of cell death in a human prostate cancer cell line. Mol Urol. 1998;2:13–8.
Clark K, Baust JM, Van Buskirk RG, Baust JG. Addition of anti-cancer agents enhancing freezing-induced prostate cancer cell death: implication of mitochondrial involvement. Cryobiology. 2004;49:45–61.
Clark DM, Rubilitto AT, Van Buskirk RG, Baust JG, Gage AA, Baust JM. Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(2):175–845.
Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int. 2005;95:1187–91.
Klossner DP, Baust JM, Van Buskirk RG, Gage AA, Baust JG. Cryoablative response of prostate cancer cells is influenced by androgen receptor expression. BJU Int. 2008;101:1310–6.
Shinohara K, Connolly JA, Presti JC, Carroll PR. Cryosurgical treatment of prostate cancer (stages T1 to T4): preliminary results. J Urol. 1996;156:115–20.
Pisters LL v, Eschenbach AC, Scott SM, Swanson DA, Dinney CP, Pettaway CA, et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997;157:921–5.
Schmidt JD, Doyle J, Larison S. Prostate cryoablation: update 1998. CA Cancer J Clin. 1998;48(4):239–53.
Arnott J. Practical illustrations of the remedial efficacy of a very low or anesthetic temperature. Lancet. 1850;2:257–9.
White AC. Possibilities of liquid air to the physician. JAMA. 1901;36:426–8.
Neel HB 3rd. Cryosurgery for the treatment of cancer. Laryngoscope. 1980;90:1–48.
Cooper IS, Lee A. Cryothalamectomy-hypothermic coagulation: a technical advance in basal ganglia surgery: preliminary report. J Am Geriatr Soc. 1961;9:714–8.
Gonder MJ, Soanes WA, Smith V. Experimental prostate surgery. Investig Urol. 1964;1:610–9.
Flocks RH, Nelson CM, Boatman DL. Perineal cryosurgery for prostatic carcinoma. J Urol. 1972;108:933–5.
Gonder MJ, Soanes WA, Shulman S. Cryosurgical treatment of the prostate. Investig Urol. 1966;3:372–8.
Megali MR, Gursel EO, Veenema RJ. Closed perineal cryosurgery in prostate cancer. New probe and technique. Urology. 1974;4(2):220–2.
Merry M, Smidebush M. Apparatus for cryosurgery. 1990. US Patent 4,946,460.
Rubinsky B, Onik G, Finkelstein JJ, Neu D, Jones S. Cryosurgical system for destroying tumors by freezing. 1994. US Patent 5,334,181.
Ando K. Cystoprostatectomy under control of ultrasono-tomagraphy. Presented at the 14th Congress of International Urologic Society. 1982.
Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J. Transrectal ultrasound guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993;72:1291–9.
Levy DA, Ross AE, El Shafei A, Krishnan N, Hatem A, Jones JS. Definition of biochemical success following primary whole gland prostate cryoablation. J Urol. 2014;192(5):1380–4.
Roach M 3rd, Hank G, Thames H Jr, Shellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendation of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–74.
Ellis DS. Cryosurgery as primary treatment for localized prostate cancer; a community experience. Urology. 2002;60(2 Suppl 1):34–9.
Shinohara K, Rhee B, Presti JC Jr, Carroll PR. Cryosurgical ablation of prostate cancer: patterns of cancer recurrence. J Urol. 1997;158:2206–9.
Benoit RM, Cohen JK, Miller RJ Jr. Cryosurgery for prostate cancer: new technology and indications. Curr Urol Rep. 2000;1:41–7.
Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE. Whole gland primary prostate cryoablation: initial results from Cryo-ON line data registry. J Urol. 2008;180:554–8.
Donnelly BJ, Saliken JC, Brasher PMA, Ernst SC, Rewcastle JC, Lau H, et al. A randomized trial of external radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer. 2010;116:323–30.
Chin JL, Al-Zahrani AA, Autran-Gomez AM, Williams AK, Bauman G. Extended follow-up oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2a-T3b). J Urol. 2012;188:1170–5.
Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN Jr. Five-year retrospective, multi-institutional pooled analysis of cancer- related outcomes after cryoablation of the prostate. Urology. 2001;57:518–23.
Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002;60:3–11.
Han KR, Cohen JK, Miller RJ, et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol. 2003;170:1126–30.
Cohen JK, Miller jr RJ, Ahmed S, Lotz MJ, Baust J. Ten year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology. 2008;71:515–8.
Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB. Results of salvage cryoablation of the prostate after radiation; identifying predictors of treatment failure and complications. J Urol. 2001;165:1937–41.
Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of first 100 patients. BJU Int. 2007;100:760–4.
Ng CK, Moussa M, Downey DB, Chin JL. Salvage cryoablation of the prostate: follow-up and analysis of predictive factors for outcome. J Urol. 2007;178:1253–7.
Bahn DK, Lee F, Silvermann P, et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: a seven year follow-up. Clin Prostate Cancer. 2003;2:111–4.
Prepelica KL, Okeke Z, Murphy A, Katz AE. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer. 2005;103:1625–30.
De La Tallie A, Benson MC, Bagiella E, Burkhardt M, Shasigh A, Olsson CA, et al. Cryoablation for localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int. 2000;85:281–6.
Cohen JK, Miller RJ, Shuman BA. Urethral warming catheter for use during cryoablation of the prostate. Urology. 1995;45:861–4.
Ellis DS, Manny TB Jr, Rewcastle JC. Cryoablation as primary treatment for localized prostate cancer followed by penile rehabilitation. Urology. 2007;69:306–10.
Wake RW, Hollabaugh RS Jr, Bond KH. Cryoablation of the prostate for localized adenocarcinoma: a preliminary experience. J Urol. 1996;155:1663–6.
Badalament RA, Bahn DK, Kim H, Kumar A, Bahn JM, Lee F. Patient-reported complications after cryoablation therapy for prostate cancer. Urology. 1999;54:295–300.
Katz AE, Preplica KL, Masson P, Benson MC, McKierman JM. Salvage cryosurgical ablation of the prostate (TCAP) for patients failing radiation: 10 year experience. J Urol. 2005;173:450. (abstract 1662)
Tatsutani K, Rubinsky B, Onik GM, et al. Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urology. 1996;48:441–7.
Gowardhan B, Greene D. Cryotherapy for the prostate: in vitro and clinical study of two new developments; advanced cryoneedles and a temperature monitoring system. BJU Int. 2007;100:295–302.
Lee F, Bahn DK, Badalament RA, et al. Cryosurgery for prostate cancer; improved glandular ablation by use of 6–8 cryoprobes. Urology. 1999;54:135–40.
Moore Y, Sofer P. Successful treatment of locally confined prostate cancer with the seed net system: preliminary multi-center results. Clinical application notes Feb 2001. Available through Galil Medical, Haifa. 2001. http//Galilmedicalcom. Accessed 7 Nov 2001.
Onik G, Narayan P, Brunelle R, et al. Saline injection into Denonvilliers’ fascia during prostate cryosurgery. J Min Ther Relat Tech. 2009;9:423–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Babaian, R.J. (2018). History and Development of Prostate Cryoablation. In: Patel, S., Moran, M., Nakada, S. (eds) The History of Technologic Advancements in Urology. Springer, Cham. https://doi.org/10.1007/978-3-319-61691-9_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-61691-9_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-61689-6
Online ISBN: 978-3-319-61691-9
eBook Packages: MedicineMedicine (R0)